Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, phase II studyto evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.